

BioAdaptives announces 5 products ready for phased entry into nutritional marketplace

25 November 2024 | News

The Company is cautiously optimistic that this will result in medically supervised proof



The Company is cautiously optimistic that this will result in medically supervised proof

BioAdaptives ushered in a new direction by appointing James Keener as CEO, Previous management retired, and Keener began focusing on products that are in demand and can change people's lives.

Six months after Keener took over, the Company is ready for the staged rollouts of five products over the next six to nine months. This is only possible because of the work and funding invested into development over a year earlier outside of BioAdaptives. Now, BioAdaptives has become the vehicle for bringing these high-demand products to market.

The first is a weight management product called Zeranovia.

“No product is in more demand today than an effective weight management product,” said Keener, adding the Company’s mission is to stay at the forefront of innovation.

Every day, commercials claim a specific supplement or food can work just as well as Ozempic, Mounjaro, or the generic GLP-1 and GIP. If this were true, pharmaceutical drug companies would go broke. A supplement can rarely work as well as a prescription medicine. However, BioAdaptives’s test results so far show that its product does work as well as prescription medication, with fewer side effects.

The Company has applied to an Institutional Review Board (IRB) for approval for a human clinical trial to prove what its earlier results have shown. It is rare for a nutraceutical company to undergo IRB approval and perform a human clinical trial. BioAdaptives believes IRB approval would provide the credibility to compete with the major players moving forward. The Company is cautiously optimistic that this will result in medically supervised proof.